CARDINAL DISTRIBUTION RAISES $ 51.5 MIL. VIA STOCK OFFERING
Executive Summary
CARDINAL DISTRIBUTION RAISES $ 51.5 MIL. VIA STOCK OFFERING and may use some of the proceeds for acquisitions to further expand the drug wholesaler's distribution operations. So far, however, no agreements have been reached, the firm said May 2. Dublin, Ohio-based Cardinal recently completed a public offering of 1.4 mil. shares of common stock with an overallotment of 210,000 shares for a total of $ 51.5 mil. The average price per share was $ 32. Cardinal is on track for another acquisition, having completed five in the past six years. The most recent addition was the June 1990 purchase of Ohio Valley-Clarksburg, a Wheeling, W.Va. company with annualized sales of more than $ 190 mil., for $ 27.1 mil. ("The Pink Sheet" July 16, T&G-12). The offering follows the wholesaler's first year of $ 1 bil.- plus sales, a more than five-fold increase from 1986 when sales were $ 197 mil. Cardinal estimates that it is now the sixth largest distributor of pharmaceuticals and health care products in the U.S. Pending any acquisitions, Cardinal will use part of the proceeds to reduce bank borrowings, which totaled $ 67.3 mil. at the time of the March 5 offering. The company has made a concerted effort to keep its debt under control. Following the Ohio Valley- Clarksburg acquisition in 1990, Cardinal filed a $ 60 mil. debenture offering with the Securities and Exchange Commission to help reduce the debt accrued in the transaction. Smith Barney, Dean Witter and A. G. Edwards helped underwrite the latest offering, as they did in the debenture offering in 1990. Cardinal also has added the underwriting and managing services of William Blair.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth